Urogen Pharma (NASDAQ:URGN) Reaches New 12-Month High - Should You Buy?

Key Points

• Urogen Pharma's stock reached a new 52-week high of $21.71, with a last traded price of $21.42, reflecting increased investor activity with over 2.28 million shares traded.
• Analysts have given Urogen Pharma a consensus target price of $32.00, with most rating the stock as a "Buy," indicating potential for substantial growth.
• The company reported a loss of ($1.05) earnings per share in its last quarterly earnings, missing estimates, but exceeded revenue projections with $24.22 million generated.

Urogen Pharma (NASDAQ:URGN - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $21.71 and last traded at $21.42, with a volume of 2282153 shares traded. The stock had previously closed at $18.88.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on URGN shares. The Goldman Sachs Group set a $16.00 price target on Urogen Pharma and gave the stock a "neutral" rating in a research report on Friday, June 13th. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the stock a "buy" rating in a research report on Friday, June 13th. Guggenheim reaffirmed a "buy" rating and set a $30.00 price objective (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of Urogen Pharma in a research report on Tuesday, August 5th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $32.00.

Urogen Pharma Price Performance

The business has a 50-day moving average of $17.69 and a two-hundred day moving average of $12.62. The company has a market cap of $990.89 million, a P/E ratio of -6.45 and a beta of 1.10.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The business had revenue of $24.22 million during the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. Equities analysts anticipate that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insider Activity

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,522 shares of the firm's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $143,971.08. Following the completion of the sale, the general counsel owned 41,492 shares of the company's stock, valued at approximately $794,156.88. This trade represents a 15.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Schoenberg sold 10,000 shares of the firm's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $17.69, for a total value of $176,900.00. Following the completion of the sale, the insider directly owned 148,229 shares of the company's stock, valued at approximately $2,622,171.01. This represents a 6.32% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 22,671 shares of company stock valued at $419,423. Corporate insiders own 4.70% of the company's stock.

Institutional Investors Weigh In On Urogen Pharma

Several institutional investors have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Urogen Pharma by 216.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock worth $48,227,000 after acquiring an additional 2,983,368 shares in the last quarter. RTW Investments LP lifted its holdings in shares of Urogen Pharma by 1.3% during the fourth quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock worth $40,841,000 after purchasing an additional 47,447 shares during the period. RA Capital Management L.P. acquired a new stake in shares of Urogen Pharma during the first quarter worth about $35,461,000. Soleus Capital Management L.P. acquired a new stake in shares of Urogen Pharma during the second quarter worth about $29,934,000. Finally, Vestal Point Capital LP lifted its holdings in shares of Urogen Pharma by 32.1% during the first quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company's stock worth $23,812,000 after purchasing an additional 522,957 shares during the period. Institutional investors and hedge funds own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.